AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tucidinostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| histone deacetylase inhibitors | 4973 | 743420-02-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Chidamide binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK1,GRK2,GRK3,ITK,JAK2,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MARK4,MELK,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK | 43 | |||
| kinase-selectivity-class | AXL,DYRK1B,GRK2,PDK4,TTK | 5 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 2021 | PMDA | HUYA JAPAN G.K. | |
| Dec. 23, 2014 | China Food and Drug Administration (CFDA) |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 224.27 | 104.81 | 51 | 367 | 53540 | 90574489 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 225.03 | 67.82 | 56 | 365 | 40405 | 42580509 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 338.94 | 80.50 | 90 | 861 | 94250 | 110494098 |
| Hypokalaemia | 91.90 | 80.50 | 40 | 911 | 182408 | 110405940 |
| Thrombocytopenia | 89.17 | 80.50 | 48 | 903 | 348837 | 110239511 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XH06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Histone deacetylase (HDAC) inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
Related Drugs by ATC class:
L01XH Histone deacetylase (HDAC) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peripheral T-cell lymphoma | indication | 109977009 | |
| Relapsed or refractory T-cell leukemia-lymphoma | indication | 110007008 | DOID:5603 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.63 | acidic |
| pKa2 | 11.87 | acidic |
| pKa3 | 4.26 | Basic |
| pKa4 | 3.32 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histone deacetylase 2 | Enzyme | INHIBITOR | IC50 | 6.80 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Histone deacetylase 1 | Enzyme | INHIBITOR | IC50 | 7.02 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Histone deacetylase 3 | Enzyme | INHIBITOR | IC50 | 7.17 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Histone deacetylase 10 | Enzyme | INHIBITOR | IC50 | 7.11 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Histone deacetylase 8 | Enzyme | INHIBITOR | IC50 | 6.14 | SCIENTIFIC LITERATURE | ||||
| Histone deacetylase 11 | Enzyme | INHIBITOR | IC50 | 6.37 | SCIENTIFIC LITERATURE | ||||
| Nicotinamide phosphoribosyltransferase | Enzyme | IC50 | 5.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 87CIC980Y0 | UNII |
| C2932486 | UMLSCUI |
| CHEBI:135918 | CHEBI |
| CHEMBL3621988 | ChEMBL_ID |
| 12136798 | PUBCHEM_CID |
| DB06334 | DRUGBANK_ID |
| 10318 | INN_ID |
| 8305 | IUPHAR_LIGAND_ID |
| D10993 | KEGG_DRUG |
| 019181 | NDDF |
| 1616493-44-7 | SECONDARY_CAS_RN |
| C000613826 | MESH_SUPPLEMENTAL_RECORD_UI |
| 87CIC980Y0 | INXIGHT DRUGS |
Pharmaceutical products:
None